journal article·2026-02Open access

Turmeric extracellular vesicles-derived “all-in-one” nanoagent enables full-cycle synergistic immunomodulation of lung cancer

Jichun Yang, Qianqian Wu, Yunqian Fu, Xiaohui Chen, Hengyi Chen, Yuhan Wang, Xiang Wu, Xin Cui, Sitong Wang, Yao Luo, Yufang Zhang, Yican Li, Yan Zhao, Zhixin Cha, Linke Shi, Xianlong Jiao, Fang Li, Yang Luo

Abstract

Lung cancer's metastatic propensity and recurrence prevalence necessitate innovative immunotherapy strategies beyond conventional single-mode regulation. We engineered low-capacity turmeric-derived extracellular vesicles (TEVs) that integrated with zeolitic imidazolate framework-8 (ZIF-8) to construct an “all-in-one” nanoagent, addressing both high drug loading nanocarriers production and immunologically cold tumor challenges. The system co-delivered chlorin e6 (Ce6) and PD-L1 siRNA, while exploited TEVs' inherent curcumin for Wnt/β-catenin pathway inhibition. Ce6-mediated photodynamic therapy (PDT) induced immunogenic cell death (ICD), releasing damage associated molecular patterns (DAMPs) to activate antigen-presenting cells (APCs). Compared with control groups, artificial intelligence model confirmed the role of curcumin in enhancing immune infiltration by 6.1-fold. PD-L1 siRNA synergistically downregulates the checkpoint expression with a 66 % reduction in vivo to prevent the immune escape. This coordinated strategy achieved full-cycle immunomodulation: (1) ICD initiated antigens release, (2) Wnt/β-catenin pathway inhibition drived T cell infiltration, and (3) PD-L1 blockade receded the immune escape. In vivo results demonstrated that 64 % primary tumor suppression and 81 % metastasis reduction versus monotherapy groups. The ZIF-8@TEV hybrid platform exhibited 12.8 % payload loading efficiency, surpassing liposomal carriers by 4.7-fold. This study established a scalable nanoengineering approach to transform immunosuppressive tumors into immunotherapy-responsive targets through a full-cycle immune coordination. • The ZeiT has 12.8 % drug loading efficiency (4.7-fold that of liposomes), addressing TEVs’ low drug-loading limitation. • The ZeiT intergrated curcumin, Ce6 and PD-L1 siRNA for full-cycle immunomodulation and overcoming immunologically cold tumors. • Ce6-mediated PDT induces ICD, releases DAMPs to activate APCs, and initiates antigen supply for immune response. • TEVs contain curcumin that inhibits the Wnt/β-catenin pathway, creating a favorable microenvironment for T cell infiltration. • PD-L1 siRNA downregulates checkpoint expression and synergistically suppresses the immune escape mechanism of tumor cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (40)

Show source-provided references
1. Cancer statistics, 2023
2. The global burden of lung cancer: current status and future trends10.1038/s41571-023-00798-3 ↗
4. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer10.1016/j.annonc.2019.10.003 ↗
5. Optimizing combination immunotherapy in lung cancer10.1038/s41588-024-02011-2 ↗
6. Immunotherapeutic approaches for small-cell lung cancer10.1038/s41571-019-0316-z ↗
7. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment10.1038/s41467-022-31926-9 ↗
8. World's first lung cancer vaccine trial launched in the UK10.1016/S1470-2045(24)00324-3 ↗
9. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages10.1016/j.immuni.2024.03.021 ↗
10. High intensity forced ultrasound-driven ferroptosis as a strategy for anti-tumor immune priming10.1016/j.apsb.2025.05.006 ↗
11. Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform 'cold' tumors into 'hot' tumors10.1186/s12943-024-02186-6 ↗
12. Activation of pyroptosis by specific organelle-targeting photodynamic therapy to amplify immunogenic cell death for anti-tumor immunotherapy
13. Cytokine storms in cancer and COVID-1910.1016/j.ccell.2020.09.019 ↗
14. Neutrophil-macrophage communication via extracellular vesicle transfer promotes itaconate accumulation and ameliorates cytokine storm syndrome10.1038/s41423-024-01174-6 ↗
15. Co-assembled binary polyphenol natural products for the prevention and treatment of radiation-induced skin injury10.1021/acsnano.4c08508 ↗
16. An alkaloid initiates phosphodiesterase 3A-schlafen 12 dependent apoptosis without affecting the phosphodiesterase activity10.1038/s41467-020-17052-4 ↗
17. Dendrimers in combination with natural products and analogues as anti-cancer agents10.1039/C7CS00550D ↗
18. Chemical modulators of mucosal associated invariant T cells10.1021/acs.accounts.1c00359 ↗
19. Immunomodulatory prodrug micelles imitate mild heat effects to reshape tumor microenvironment for enhanced cancer immunotherapy10.1021/acsnano.3c11186 ↗
20. Plant exosomes fused with engineered mesenchymal stem cell-derived nanovesicles for synergistic therapy of autoimmune skin disorders10.1002/jev2.12361 ↗
21. The biology, function, and applications of exosomes in cancer10.1016/j.apsb.2021.01.001 ↗
22. Biomimetic electrodynamic nanoparticles comprising ginger-derived extracellular vesicles for synergistic anti-infective therapy10.1038/s41467-022-34883-5 ↗
23. Thomas Gajewski correlation of WNT/β-catenin pathway activation with immune exclusion across most human cancers
24. Near-infrared light-activatable upconversion nanoparticle/curcumin hybrid nanodrug: a potent strategy to induce the differentiation and elimination of glioma stem cells10.1007/s42114-024-00886-7 ↗
25. Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment10.1016/j.ymthe.2021.08.028 ↗
26. Phloem sap from melon plants contains extracellular vesicles that carry active proteasomes which increase in response to aphid infestation10.1002/jev2.12517 ↗
27. Biomimetic grapefruit-derived extracellular vesicles for safe and targeted delivery of sodium thiosulfate against vascular calcification10.1021/acsnano.3c05261 ↗
28. Technology insight: plant-derived vesicles-how far from the clinical biotherapeutics and therapeutic drug carriers?10.1016/j.addr.2021.114108 ↗
29. Isolation of cabbage exosome-like nanovesicles and investigation of their biological activities in human cells
30. Development and evaluation of reconstructed nanovesicles from turmeric for multifaceted obesity intervention10.1021/acsnano.4c05309 ↗
31. Formulation of metal-organic framework-based drug carriers by controlled coordination of methoxy PEG phosphate: boosting colloidal stability and redispersibility10.1021/jacs.1c03943 ↗
32. Efficient oral insulin delivery with sustained release by folate-conjugated metal-organic framework nanoparticles10.1016/j.matt.2024.101948 ↗
33. Ultra-efficient radio-immunotherapy for reprogramming the hypoxic and immunosuppressive tumor microenvironment with durable innate immune memory10.1016/j.biomaterials.2023.122303 ↗
34. Hypocrellin A-based photodynamic action induces apoptosis in A549 cells through ROS-mediated mitochondrial signaling pathway10.1016/j.apsb.2018.12.004 ↗
35. Self-Immolative photosensitizers for self-reported cancer phototheranostics10.1021/jacs.3c01666 ↗
36. Mitochondria-targeting type-I photodrug: harnessing caspase-3 activity for pyroptotic oncotherapy10.1021/jacs.4c01929 ↗
37. Intracellular photoactivation of caspase-3 by molecular glues for spatiotemporal apoptosis induction10.1021/jacs.0c01823 ↗
38. Biomineralized two-enzyme nanoparticles regulate tumor glycometabolism inducing tumor cell pyroptosis and robust antitumor immunotherapy10.1002/adma.202206851 ↗
39. Multifunctional magnetic nanoclusters can induce immunogenic cell death and suppress tumor recurrence and metastasis10.1021/acsnano.2c06776 ↗
40. Inhibitory microenvironment remodeling enhances STING activation for solid tumor immunotherapy